Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman’s first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2018. In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence. In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2018.

In method (d) the 1981 melanoma is counted for the melanoma and all sites limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.

In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.